Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid generation of high-quality proteins and therapeutic candidates, Absci effectively shortens development timelines and lowers associated costs, establishing itself as a key innovator within the biopharmaceutical sector. The company's robust pipeline, complemented by strategic partnerships, underscores its commitment to advancing next-generation therapies that address critical medical needs and improve patient outcomes.
| Revenue (TTM) | $1.56M |
| Gross Profit (TTM) | $-84.23M |
| EBITDA | $-119.51M |
| Operating Margin | -10742.00% |
| Return on Equity | -57.70% |
| Return on Assets | -34.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $1.44 |
| Price-to-Book | 6.79 |
| Price-to-Sales (TTM) | 1070.80 |
| EV/Revenue | 944.95 |
| EV/EBITDA | -0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -46.40% |
| Shares Outstanding | $171.61M |
| Float | $163.79M |
| % Insiders | 11.84% |
| % Institutions | 87.25% |
Volatility is currently expanding
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
VANCOUVER, Wash. and NEW YORK, Sept.
On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six positions.
RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half of 2028 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter ended June 30, 2026.
Here is how Absci Corporation (ABSI) and Acadia Healthcare (ACHC) have performed compared to their sector so far this year.
VANCOUVER, Wash. and NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the second quarter 2026 after market close on Tuesday, August 11, 2026.
The average of price targets set by Wall Street analysts indicates a potential upside of 28.3% in ABSCI CORP (ABSI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABSI and any ticker you trade — then tracks every position and per-strategy win rate.
